What ICH Q9(R1) changed in quality risk management: subjectivity, formality, risk-based decisions and product availability, with worked examples and a practical framework.
Where nitrosamine and NDSRI control stands after FDA's August 2025 progress report change: CPCA limits, EMA Article 5(3) Q&A, mitigation and submission pathways.
FDA's voluntary Quality Management Maturity Program is quietly building toward a real quality rating system. Here's what it measures and what's at stake.
